The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Exciting news at the ASH 2021 plenary scientific session
Mikkael Sekeres, MD, MS, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, discusses the exciting work that will be on display at the plenary scientific session at this year’s ASH annual congress. Topics include how SARS-CoV-2 augments procoagulant activity, the safety and efficacy of an siRNA therapeutic to restore thrombin generation and rebalance hemostasis in patients with hemophilia A or B, and observations of reduced Alzheimer’s disease risk in people with clonal hematopoiesis of indeterminate potential (CHIP). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
